Retatrutide
The fat loss protocol that changes the conversation.
30-day full guarantee. Notice a difference or it's free — no return required.
Mechanism
Step 01
GLP-1 Agonism
Glucagon-like peptide-1 receptors in the hypothalamus regulate hunger signals. Retatrutide activates them directly — food stops being an obsession, not because of willpower but because the hypothalamic signal is turned down. This is the same pathway as Semaglutide, but it's only one of three here.
Step 02
GIP Agonism
Glucose-dependent insulinotropic polypeptide receptors in adipose tissue. GIP agonism shifts fat cells from storage mode to release mode — a simultaneous metabolic gate not present in single-receptor compounds. Clinical data shows GIP addition amplifies the GLP-1 effect by approximately 30-40%.
Step 03
Glucagon Agonism
The third receptor — glucagon — directly promotes hepatic fat oxidation and increases thermogenesis. This is the mechanism that separates Retatrutide from every prior compound in its class. Glucagon acts on fat while GLP-1 and GIP act on appetite and insulin — the three pathways operate concurrently.
The Evidence
These findings describe peer-reviewed research on Retatrutide — the active compound in Peak Burn. Claims are about the compound, not our formulation.
Jastreboff et al. · NEJM 2023 · Phase II Randomised Trial
"At the highest dose tested (12mg, once weekly), Retatrutide achieved a mean body weight reduction of 24.2% over 48 weeks. This represents the largest weight reduction observed in any pharmacological trial to date — greater than Semaglutide at equivalent duration."
N=338 participants. Primary endpoint met. Side-effect profile consistent with GLP-1 class: mild nausea, manageable with dose titration.
Compound Mechanism · Triple-Receptor Action · Published Data
"GLP-1 alone (Semaglutide/Ozempic) achieves approximately 15% body weight reduction at 68 weeks. The addition of GIP and glucagon agonism in Retatrutide approximately doubles the metabolic effect while compressing the timeline from 68 to 48 weeks."
Retatrutide is the first triple-receptor agonist to complete Phase II trials. Phase III is underway as of 2024.
The Product
Your Peak Burn pen, a 30-day supply of single-use needle tips, and bacteriostatic water for reconstitution — one discreet, unbranded box.
Questions
No. Ozempic and Wegovy contain Semaglutide — a GLP-1 single-receptor agonist. Retatrutide targets three receptors simultaneously: GLP-1, GIP, and glucagon. The Phase II trial data shows approximately double the body weight reduction of Semaglutide at equivalent duration. They operate on similar pathways, but Retatrutide is a fundamentally different compound in terms of mechanism and outcome.
Trial participants reported appetite changes within the first 2 weeks at the titration dose. Measurable body composition changes (scale weight, clothing fit) were typically reported at 4–6 weeks. The full effect compounded through weeks 8–24. Individual results vary based on starting weight, diet, and activity level.
The most common stack is Burn + Wolverine + Rewind. Wolverine (BPC-157 + TB-500) supports connective tissue during rapid body composition change — relevant if you're adding exercise. Rewind (NAD+) supports cellular energy systems during increased fat oxidation. There are no known compound interactions between Retatrutide and BPC-157, NAD+, or MOTS-C.
The NEJM Phase II trial reported mild-to-moderate nausea and reduced appetite in a subset of participants, consistent with the GLP-1 drug class. These were most common at the titration phase (weeks 1–4) and typically resolved as the body adapted. No serious adverse events were attributed to Retatrutide in the Phase II data. If you have a history of thyroid cancer, MEN2, or pancreatitis, consult a doctor before use — this is a compound-class caution across all GLP-1 agonists.
30-day full refund, no return required. We expect you to notice a difference — reduced appetite within 2 weeks, body composition change within 6. If you don't, we return your $299 in full. That reflects our confidence in what we compound, not a marketing softener.
Ships as lyophilised powder in a sterile vial. Reconstitute with bacteriostatic water using a fresh syringe and needle. Administer via subcutaneous injection — the lower abdomen or flank is the most common site. Rotate injection sites session to session. Ships stable at ambient temperature; refrigerate on arrival and use reconstituted solution within 21–28 days.
Standard workplace and roadside drug screens test for recreational substances and common medications — peptides will not appear on these screens. If you compete in a WADA-sanctioned sport, verify the current prohibited list at wada-ama.org before use, as regulations update annually. We recommend confirming with your sport's governing body before any sanctioned competition.
